<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611766</url>
  </required_header>
  <id_info>
    <org_study_id>V02_2010_10</org_study_id>
    <secondary_id>SGOG OV2</secondary_id>
    <nct_id>NCT01611766</nct_id>
  </id_info>
  <brief_title>Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?</brief_title>
  <official_title>Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and
      validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare overall survival (OS) in patients with
      platinum-sensitive recurrent ovarian cancer with a positive SCR score randomized to secondary
      cytoreductive surgery followed by chemotherapy versus chemotherapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 36 months after last patient randomized</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Progression-free survival is defined as interval between date of randomization and 2nd relapse/progression or death (whatever occurs first), assessed up to 36 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline, 6, 12, 24 and 60 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications incidence</measure>
    <time_frame>From the operation until after 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>secondary cytoreductive surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCR followed by chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>platinum-based chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Secondary Cytoreductive Surgery</intervention_name>
    <description>Complete Cytoreduction</description>
    <arm_group_label>secondary cytoreductive surgery</arm_group_label>
    <other_name>Debulking Surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvage Chemotherapy</intervention_name>
    <arm_group_label>secondary cytoreductive surgery</arm_group_label>
    <arm_group_label>Salvage Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at recurrence â‰¥ 18 years

          -  Patients with platinum-sensitive, first relapsed epithelial ovarian, primary
             peritoneal, or fallopian tube cancer (EOC, PPC, FTC), which is defined as those with
             treatment -free interval of 6 months or more.

          -  A complete secondary cytoreduction predicting score, iMODEL [Tian WJ, Ann Surg Oncol
             2012,19(2):597-604]&lt;=4.7, including FIGO stage (0 or 0.8); residual disease after
             primary surgery (0 or 1.5); Progression-free interval (0 or 2.4); PS ECOG (0 or 2.4);
             Ca125 (0 or 1.8); and ascites at recurrence (0 or 3.0). If PI and CO-PI reach
             consensus that the recurrent tumor detected by PET/CT could be completely resected,
             the index of CA125 could be scored as 0. (Revised on 09/30/2013)

          -  Assessed by the experienced surgeons, complete resection of all recurrent disease is
             possible. If single lesion outside the peritoneal cavity can be resected, MRI/CT or
             PET/CT scan should be performed to exclude simultaneous intra-abdominal lesions.

          -  Patients who have given their signed and written informed consent and their consent.

        Exclusion Criteria:

          -  Patients with borderline tumors as well as non-epithelial tumors.

          -  Patients for interval-debulking, or for second-look surgery, or palliative surgery
             planned.

          -  Impossible to assess the resectability or evaluate the score. Radiological signs
             suggesting complete resection is impossible.

          -  More than one prior chemotherapy.

          -  Second relapse or more

          -  Patients with second or other malignancies who have been treated by surgery, if the
             treatment might interfere with the treatment of relapsed ovarian cancer or if major
             impact on prognosis is expected.

          -  Progression during chemotherapy or recurrence within 6 months after first-line therapy

          -  Any contradiction not allowing surgery and/or chemotherapy

               1. Accompanied by hypoxia serious chronic obstructive pulmonary disease

               2. Uncontrolled hypertension, cerebrovascular accident/ Stroke, myocardial infarct,
                  unstable angina, untreated thrombosis, chronic congestive heart failure, or
                  serious arrhythmia in need of medicine.

               3. Severe hepatitis, history of liver disease, nephrotic syndrome, renal
                  insufficiency

               4. Active ulcer history, abdominal wall fistula, perforation of gastrointestinal
                  tract, or Intra-abdominal abscess, or simultaneously apply treatment/prevent
                  ulcers therapy.

               5. Uncontrolled diabetes

               6. Uncontrolled epilepsy need long-term antiepileptic treatment.

          -  Any medication induced considerable risk of surgery, e.g. estimated bleeding due to
             oral anticoagulating agents, or bevacizumab)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongyu Zang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Huang, MD, PhD</last_name>
    <phone>+862164175590</phone>
    <email>smilehuangxiao@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuting Luan, RN</last_name>
    <phone>+862164175590</phone>
    <email>fudanGOG@gmail.com; yutingluan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihong Jiu, MD, PhD</last_name>
      <phone>86 20 87343088</phone>
      <email>liujih@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao Huang, MD,PhD</last_name>
      <phone>+862164175590</phone>
      <email>smilehuangxiao@163.com</email>
    </contact>
    <investigator>
      <last_name>Rongyu Zang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Jiang, MD</last_name>
      <phone>86 21 64041990</phone>
      <phone_ext>2905</phone_ext>
      <email>rong_junzhu@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqing Zhu, MD</last_name>
      <phone>86 571 8822222</phone>
      <email>zjq-hz@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ShanghaiGOG.org</url>
    <description>Shanghai Gynecologic Oncology Group</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondary cytoreductive surgery</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>surgery</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

